Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Acceptability of Cepacol Canela Power
NCT00687037Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2008
- Primary completion
- Feb 2008
- Modality
- Conventional Liposomes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cetylpyridinium chloride in dental plaque and gingivitis, sponsored by Sanofi. Primary endpoints: Adverse Reactions and Intensity at 21 days and Physical Attributes Questionnaire at 21 days. Started Jan 2008; status: completed.
02
Drugs
cetylpyridinium chloride
03
Conditions
dental plaquegingivitis
Beyond the preview
Go deeper on NCT00687037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687037.